Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Jun. 2026,
Tandem Diabetes Care paidMXN0 Mil more to buy back shares than it received from issuing new shares.
It receivedMXN0 Mil from issuing more debt.
It paidMXN0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedMXN0 Mil from paying cash dividends to shareholders.
It receivedMXN0 Mil on other financial activities.
In all, Tandem Diabetes CarespentMXN0 Mil on financial activities for the
three
months ended in Jun. 2026.
Tandem Diabetes Care (MEX:TNDM) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Tandem Diabetes Care's issuance of stock for the
three
months ended in Jun. 2026 was MXN0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Tandem Diabetes Care's repurchase of stock for the
three
months ended in Jun. 2026 was MXN0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Tandem Diabetes Care's net issuance of debt for the
three
months ended in Jun. 2026 was MXN0 Mil.
Tandem Diabetes Care receivedMXN0 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Tandem Diabetes Care's net issuance of preferred for the
three
months ended in Jun. 2026 was MXN0 Mil.
Tandem Diabetes Care paidMXN0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Tandem Diabetes Care's cash flow for dividends for the
three
months ended in Jun. 2026 was MXN0 Mil.
Tandem Diabetes Care receivedMXN0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Tandem Diabetes Care's other financing for the
three
months ended in Jun. 2026 was MXN0 Mil.
Tandem Diabetes Care receivedMXN0 Mil on other financial activities.
Tandem Diabetes Care Cash Flow from Financing Related Terms
Tandem Diabetes Care Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Tandem Diabetes Care's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care Cash Flow from Financing Chart
Tandem Diabetes Care Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Tandem Diabetes Care's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN5,000 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of MXN5,000 Mil mean?
Tandem Diabetes Care (MEX:TNDM) has a Cash Flow from Financing of MXN5,000 Mil as of Jun. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Tandem Diabetes Care and its competitors.
Is Tandem Diabetes Care's Cash Flow from Financing too high?
Tandem Diabetes Care's current Cash Flow from Financing is MXN5,000 Mil. Overall, Tandem Diabetes Care has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Cash Flow from Financing compare to AVNS and IRMD?
Tandem Diabetes Care's Cash Flow from Financing of MXN5,000 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Devices & Instruments company?
A good Cash Flow from Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Tandem Diabetes Care and its competitors. Tandem Diabetes Care's current Cash Flow from Financing is MXN5,000 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Tandem Diabetes Care (MEX:TNDM) has a current Cash Flow from Financing of MXN5,000 Mil. The stock's GF Value™ is MXN762.96, compared to a current price of MXN745.00 — trading 2.4% below its estimated fair value. The current Cash Flow from Financing is MXN5,000 Mil. Tandem Diabetes Care's overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Tandem Diabetes Care (MEX:TNDM), the current Cash Flow from Financing is MXN5,000 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (MEX:TNDM) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of MXN745.00 is trading 2.4% below its estimated GF Value™ of MXN762.96.
Key valuation signals for MEX:TNDM:
Cash Flow from Financing: MXN5,000 Mil
GF Value™: MXN762.96 vs. price of MXN745.00 (2.4% below fair value)
No single metric tells the full story. See the MEX:TNDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
73GF Score
Get the complete analysis for MEX:TNDM
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TNDM has been successfully added to your 
